Intellia Therapeutics (NTLA) Research Coverage Started at Credit Suisse Group

Stock analysts at Credit Suisse Group started coverage on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Monday, MarketBeat Ratings reports. The brokerage set a “neutral” rating and a $24.00 price target on the stock. Credit Suisse Group’s price target suggests a potential upside of 29.59% from the stock’s current price.

A number of other equities analysts also recently commented on the stock. Raymond James initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, September 20th. They issued a “market perform” rating on the stock. BidaskClub raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, September 15th. ValuEngine downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Zacks Investment Research downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $57.50 price target on shares of Intellia Therapeutics in a report on Friday, August 24th. One analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $38.93.

Shares of NTLA stock opened at $18.52 on Monday. Intellia Therapeutics has a 52 week low of $16.33 and a 52 week high of $35.99. The firm has a market capitalization of $860.89 million, a PE ratio of -9.85 and a beta of 3.14.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Wednesday, August 1st. The company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.03. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The business had revenue of $7.68 million for the quarter, compared to the consensus estimate of $6.39 million. During the same quarter last year, the firm posted ($0.45) EPS. The business’s revenue for the quarter was up 30.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Intellia Therapeutics will post -1.97 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Patriot Financial Group Insurance Agency LLC acquired a new stake in Intellia Therapeutics during the 3rd quarter valued at $116,000. First Trust Advisors LP grew its holdings in Intellia Therapeutics by 53.4% during the 3rd quarter. First Trust Advisors LP now owns 160,303 shares of the company’s stock valued at $4,588,000 after purchasing an additional 55,798 shares in the last quarter. Chevy Chase Trust Holdings Inc. grew its holdings in Intellia Therapeutics by 13.1% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 742,024 shares of the company’s stock valued at $21,237,000 after purchasing an additional 86,142 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Intellia Therapeutics by 113.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 17,100 shares of the company’s stock valued at $489,000 after purchasing an additional 9,100 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. acquired a new stake in Intellia Therapeutics during the 3rd quarter valued at $141,000. 66.47% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Recommended Story: How is a Moving Average Calculated?

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply